These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28711363)

  • 21. Perioperative ischaemic stroke in patients with atrial fibrillation after temporary cessation of anticoagulation for elective surgery.
    Xu Y; Maddula M
    N Z Med J; 2018 Sep; 131(1482):80-83. PubMed ID: 30235195
    [No Abstract]   [Full Text] [Related]  

  • 22. D-Dimer versus International Normalized Ratio of Prothrombin Time in Ischemic Stroke Patients Treated with Sufficient Warfarin.
    Yamamoto R; Nakae Y; Tanaka F; Johkura K
    J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1781-1785. PubMed ID: 27103270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
    Yasaka M; Minematsu K; Toyoda K; Yamagami H; Yoshimura S; Nagao T; Mori E; Hirano T; Hamasaki T; Yamaguchi T
    J Stroke Cerebrovasc Dis; 2016 Jun; 25(6):1342-8. PubMed ID: 26987488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (
    Patti G; Lucerna M; Pecen L; Siller-Matula JM; Cavallari I; Kirchhof P; De Caterina R
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28736385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. North American Thrombosis Forum, AF Action Initiative Consensus Document.
    Ruff CT; Ansell JE; Becker RC; Benjamin EJ; Deicicchi DJ; Mark Estes NA; Ezekowitz MD; Fanikos J; Fareed J; Garcia D; Giugliano RP; Goldhaber SZ; Granger C; Healey JS; Hull R; Hylek EM; Libby P; Lopes RD; Mahaffey KW; Mega J; Piazza G; Sasahara AA; Sorond FA; Spyropoulos AC; Walenga JM; Weitz JI
    Am J Med; 2016 May; 129(5 Suppl):S1-S29. PubMed ID: 27126598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
    Dillinger JG; Aleil B; Cheggour S; Benhamou Y; Béjot Y; Marechaux S; Delluc A; Bertoletti L; Lellouche N
    Arch Cardiovasc Dis; 2018 Feb; 111(2):85-94. PubMed ID: 28988597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
    Collings SL; Vannier-Moreau V; Johnson ME; Stynes G; Lefèvre C; Maguire A; Asmar J; Bizouard G; Duhot D; Mouquet F; Fauchier L
    Arch Cardiovasc Dis; 2018 May; 111(5):370-379. PubMed ID: 29398546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?
    Olesen JB; Torp-Pedersen C
    Thromb Haemost; 2015 Jun; 113(6):1165-9. PubMed ID: 25743201
    [No Abstract]   [Full Text] [Related]  

  • 29. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulant Therapy in Atrial Fibrillation for Stroke Prevention: Assessment of Agreement Between Clinicians' Decision and CHA2DS2-VASc and HAS-BLED Scores.
    Balaghi-Inalou M; Parsa SA; Gachkar L; Andalib S
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):61-64. PubMed ID: 29076078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion.
    Simonsen CZ; Steiner T; Tietze A; Damgaard D
    J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e133-4. PubMed ID: 24103671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First Diagnosis of Atrial Fibrillation at the Time of Stroke.
    Borowsky LH; Regan S; Chang Y; Ayres A; Greenberg SM; Singer DE
    Cerebrovasc Dis; 2017; 43(3-4):192-199. PubMed ID: 28208140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.
    Williams BA; Evans MA; Honushefsky AM; Berger PB
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation.
    Yao X; Abraham NS; Alexander GC; Crown W; Montori VM; Sangaralingham LR; Gersh BJ; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
    Potpara TS; Lip GY
    Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct oral anticoagulants in the early phase of non-valvular atrial fibrillation-related ischemic stroke in very old patients undergoing systemic thrombolysis and/or mechanical thrombectomy.
    Masotti L; Moroni F; Vannucchi V; Grifoni E; Dei A; Landini G
    Geriatr Gerontol Int; 2018 Aug; 18(8):1304-1305. PubMed ID: 30136389
    [No Abstract]   [Full Text] [Related]  

  • 37. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
    Hylek EM
    Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
    [No Abstract]   [Full Text] [Related]  

  • 38. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients.
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Marín F
    Thromb Haemost; 2017 Jun; 117(7):1448-1454. PubMed ID: 28331926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).
    Lip GY; Halperin JL; Petersen P; Rodgers GM; Pall D; Renfurm RW
    J Thromb Haemost; 2015 Aug; 13(8):1405-13. PubMed ID: 26052866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
    Xu H; Ruff CT; Giugliano RP; Murphy SA; Nordio F; Patel I; Shi M; Mercuri M; Antman EM; Braunwald E
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.